F
Filip Dumitru
Publications - 3
Citations - 1734
Filip Dumitru is an academic researcher. The author has contributed to research in topics: Ramucirumab & Cancer. The author has an hindex of 2, co-authored 3 publications receiving 1479 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,G. Aprile,David Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Zalcberg,John Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M. Liepa,Ling Gao,Jonathan D. Schwartz,Josep Tabernero +24 more
TL;DR: Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer.
Journal ArticleDOI
Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).
Charles S. Fuchs,Josep Tabernero,Jiri Tomasek,Ian Chau,Bohuslav Melichar,Howard Safran,Mustapha Tehfe,Filip Dumitru,Eldar Topuzov,Luis Schlittler,Anghel Adrian Udrea,William Campbell,Stephen Brincat,Michael Emig,Symantha Melemed,Rebecca R. Hozak,David Ferry,William C. Caldwell,Jaffer A. Ajani +18 more
TL;DR: RAM, a recombinant human IgG1 monoclonal antibody specific for VEGF receptor 2 (VEGFR2), inhibiting Vascular endothelial growth factors (VEGFs) in tumor angiogenesis is described.
Journal ArticleDOI
Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.
Charles S. Fuchs,Kei Muro,Jiri Tomasek,Eric Van Cutsem,Jae Yong Cho,Sang Cheul Oh,Howard Safran,György Bodoky,Ian Chau,Yasuhiro Shimada,Filip Dumitru,Salah-Eddin Al-Batran,Rodolfo Passalacqua,Atsushi Ohtsu,Michael Emig,David Ferry,Kumari Chandrawansa,Yanzhi Hsu,Andreas Sashegyi,Hansjochen Wilke +19 more
TL;DR: This phase III, randomized, double-blind studies of RAM in metastatic gastroesophageal junction and gastric adenocarcinoma following progressive disease on first-line platinum- and/or fluoropyrimidine-containing therapy identified prognostic factors for OS that were stratified by treatment and geographic region.